No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARQT240517C10000
- 0.20
- 0.000.00%
15min DelayClose May 13 15:56 ET
0.20High0.15Low
0.20Open0.20Pre Close171 Volume2.41K Open Interest10.00Strike Price2.75KTurnover210.15%IV27.35%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.20Time Value100Contract SizeAmericanOptions Type0.1928Delta0.1503Gamma45.66Leverage Ratio-0.0581Theta0.0002Rho8.80Eff Leverage0.0024Vega
Intraday
- 5D
- 1D
News
The Journal Of Clinical And Aesthetic Dermatology Published Arcutis Biotherapeutics' Outcomes Of A Comprehensive Evaluation By An Expert Dermatologist Panel Assessing The Formulation Ingredients Of ZORYVE Topical Foam, 0.3%
Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on re
Expert Panel Review Further Validates Use of ZORYVE (Roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation
Arcutis Biotherapeutics(ARQT.US) Officer Sells US$40,901.64 in Common Stock
$Arcutis Biotherapeutics(ARQT.US)$ Officer Moore Matthew Richard sold 4,681 shares of common stock on May 2, 2024 at an average price of $8.7378 for a total value of $40,901.64.Source: Announcement Wh
Form 144 | Arcutis Biotherapeutics(ARQT.US) Officer Proposes to Sell 120.43K in Common Stocks
SEC FILLINGS DISCLOSED/ May 2, $Arcutis Biotherapeutics(ARQT.US)$ Officer Watanabe Todd Franklin intends to sell 13,783 shares of its common stock on May 2, with a total market value of approximately
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology,
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Shareholders in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The consensus estimated reven
Comments
Arcutis' CEO, Frank Watanabe, commends Todd Tucker's promotion to CHRO, praising his leadership in people-centered programs. Tucker's leadership is expected to boost the company's growth and workforce productivity.
Press Release: Arcutis Promotes Todd Tucker to Chief Human Resources Officer 1
$Arcutis Biotherapeutics(ARQT.US$ Ive posted lots of great news here! Especially since early/mid December! And with the exception of a few, the chat is dead! Which is kinda surprising considering the massive increase in price overall from my December 15/17 post! Is it because so many are enjoying the slow but super untrend and dont want to bring attention to the massive gains! Hehehe. Or did not many actually join in? Hehehe! Just thinking outloud! ![]()
1
4
Despite strong revenue growth, the company's P/S ratio remains stagnant, possibly due to waning performance expectations. Its shares have risen, aligning the P/S with industry median. However, its subdued growth projections compared to the industry make its current P/S ratio surprising. Predicted revenues may not sustain positive sentiment, risking shareholders' investments and potential investors paying a premium.
Since the beginning of this year, $NVIDIA(NVDA.US$ has been leading a group of semiconductor and AI stocks to further rise in response to the breakthroughs in AI technology and a booming industry outlook. However, an increasing number of investors have started to fret over the potential risks behind the high valuations of AI stocks and are scouting for alternative investment opportunities. Some of them have shifted their focus to biotech stocks...
59
3
1
4
Read more